Abstract
Emerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with several aspects of tumorigenesis and miRNA loci have been mapped to frequently altered cancerassociated genomic regions. Inhibition or augmentation of miRNA expression in cancer cells impacts gene expression and affects cell proliferation and survival. Hence, cancer-associated miRNAs may be regarded as a new class of non-coding tumour suppressors and oncogenes capable of regulating several key signalling pathways.
Current Pharmaceutical Biotechnology
Title: MicroRNAs in Tumorigenesis
Volume: 8 Issue: 6
Author(s): Kai Ove Skaftnesmo, Lars Prestegarden, David R. Micklem and James B. Lorens
Affiliation:
Keywords: RNA, microRNA, cancer
Abstract: Emerging evidence suggests a class of non-coding RNAs termed microRNAs (miRNAs) play a key role in cancer. Since their original discovery in C. elegans in 1993 it has become evident that miRNAs are responsible for an entirely new mechanism of posttranscriptional gene regulation. miRNA expression is widespread in mammalian cells and notably altered in several cancer types. miRNA expression patterns correlate with several aspects of tumorigenesis and miRNA loci have been mapped to frequently altered cancerassociated genomic regions. Inhibition or augmentation of miRNA expression in cancer cells impacts gene expression and affects cell proliferation and survival. Hence, cancer-associated miRNAs may be regarded as a new class of non-coding tumour suppressors and oncogenes capable of regulating several key signalling pathways.
Export Options
About this article
Cite this article as:
Skaftnesmo Ove Kai, Prestegarden Lars, Micklem R. David and Lorens B. James, MicroRNAs in Tumorigenesis, Current Pharmaceutical Biotechnology 2007; 8 (6) . https://dx.doi.org/10.2174/138920107783018390
DOI https://dx.doi.org/10.2174/138920107783018390 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Quality of Life Assessments in Colorectal Cancer Surgery. A Review
Current Cancer Therapy Reviews Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine 4'-Thionucleosides as Potent and Selective A<sub>3</sub> Adenosine Receptor Ligands
Current Organic Chemistry Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design A Review on Antiproliferative and Apoptotic Activities of Natural Honey
Anti-Cancer Agents in Medicinal Chemistry Chemopreventive Agents Alters Global Gene Expression Pattern: Predicting their Mode of Action and Targets
Current Cancer Drug Targets Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry MGBG in Combined Anticancer Chemotherapy
Letters in Drug Design & Discovery 10 Years of SELDI: What Have we Learnt?
Current Proteomics Drug Encapsulated Nanoparticles for Treating Targeted Cells
Current Medicinal Chemistry Metabolic Cooperation in Testis as a Pharmacological Target: From Disease to Contraception
Current Molecular Pharmacology Management of Vaginal Cancer
Reviews on Recent Clinical Trials MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry Specific Hemosiderin Deposition in Spleen Induced by a Low Dose of Cisplatin: Altered Iron Metabolism and Its Implication as an Acute Hemosiderin Formation Model
Current Drug Metabolism Synthetic Lethality-Based Therapeutics: Perspectives for Applications in Colorectal Cancer
Current Cancer Drug Targets Endometriosis and Gynecological Cancer
Current Women`s Health Reviews Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets